BLFS250117C30000
- 0.41
- 0.000.00%
BioLife Solutions Newsroom
Craig-Hallum Maintains BioLife Solutions(BLFS.US) With Buy Rating
Northland Securities Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $31
Maxim Group Initiates BioLife Solutions(BLFS.US) With Buy Rating, Announces Target Price $34
Northland Capital Markets Maintains Outperform on BioLife Solns, Raises Price Target to $31
BioLife Solns Analyst Ratings
Maxim Group Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $34
TD Cowen Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $31
KeyBanc Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $33
TD Cowen Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $31
TD Cowen Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $31
TD Cowen Remains a Buy on BioLife Solutions (BLFS)
Benchmark Co. Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $30
Jefferies Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $31
Jefferies Initiates BioLife Solutions(BLFS.US) With Buy Rating, Announces Target Price $31
BioLife Solns Analyst Ratings
KeyBanc Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $33
Northland Securities Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $28
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Sinopharm Group Co (OtherSHTDF)
Maxim Group Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $30
H.C. Wainwright Maintains BioLife Solutions(BLFS.US) With Buy Rating, Cuts Target Price to $27